Clinical trial
A Phase 1 Study of MK-1697 in Participants With Advanced Solid Tumors
NCT03515824 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of MK-1697 in Participants With Advanced Solid Tumors
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 13, 2018
- Completion date
- February 18, 2020
- Enrollment
- 22 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.